Cancer genome sequencing has revealed considerable variation in somatic mutation rates across the human genome, with mutation rates elevated in heterochromatic late replicating regions and reduced in early replicating euchromatin [1] [2] [3] [4] [5] . Multiple mechanisms have been suggested to underlie this 2,6-10 , but the actual cause is unknown. Here we identify variable DNA mismatch repair (MMR) as the basis of this variation. Analysing 17 million single-nucleotide variants from the genomes of 652 tumours, we show that regional autosomal mutation rates at megabase resolution are largely stable across cancer types, with differences related to changes in replication timing and gene expression. However, mutations arising after the inactivation of MMR are no longer enriched in late replicating heterochromatin relative to early replicating euchromatin. Thus, differential DNA repair and not differential mutation supply is the primary cause of the largescale regional mutation rate variation across the human genome.
We examined 1 megabase (Mb) mutation densities along 652 fully sequenced human cancer genomes with .3,000 single-nucleotide variants (SNVs) per genome, originating from 16 tissues. This threshold enables more robust estimates of regional SNV densities in the examined samples, but it excludes cancer types with a very low mutation burden (Methods). Despite vastly different mutational loads between tissues of origin and between individual tumours 11 , the relative regional densities were, overall, consistent between samples. In a principal components analysis (PCA), the first principal component (PC1) corresponds closely to the average densities over all samples (R 2 5 0.99) and captures 86.2% of the non-random variability between the 1 Mb windows (Fig. 1a-c ). This estimate of baseline variability per PC (Methods) encompasses the non-biological sources of randomness in the data (for example, low mutation counts per bin in some cancer types) but it may also include genuine biological variability, if it is particular to individual tumour genomes. The second most prominent PCA trend (PC2, 5.9% variability; Fig. 1a , d) precisely captures the known hypermutation of the X chromosome in a subset of tumours 12 . Across the 652 tumours, we estimate that a further 7.9% of non-random variability exists that is not explained by the general pattern of regional rates or by the hypermutation of X (in PC3-8, with 4.4% in PC3 only; Fig. 1a, b) .
This signal can, in part, be ascribed to tissue-specific mutation rates: cancer samples from 7/16 tissues were significantly shifted in the distribution of their PC3 loadings (Mann-Whitney test, false discovery rate (FDR) , 1%). Liver, colorectal and B-lymphocyte tumours were differentiated by lower PC3 loading scores, whereas melanoma, breast, ovarian and lung tumours had higher PC3 loadings (tissues highlighted in Fig. 1e ). To examine if these significant regional rate changes are associated to DNA replication timing changes, we used Repli-Seq data from ENCODE cell lines as a proxy for the changes occurring in the cancers of the corresponding tissues. In all cases, the correlation of the cell-line-specific Repli-Seq signal to the cancer-type-specific 1 Mb mutation rates was most prominent in the cancer type matching the cell line, with a significant difference from the non-matching cancer types (FDR , 10%, Fig. 1f) . Similarly, the changes in average gene expression levels in 1 Mb windows in tumour samples paralleled the changes in mutation rates in the same samples, with significantly stronger correlations for the matching cancer type (FDR , 10%, Fig. 1g ; example in Extended Data Fig. 1a, b) .
Visualizing the cancer samples in a PC plot revealed a group of outliers in a low-density area of the plot with extreme PC3 and PC4 loadings (box in Fig. 1e ). These samples derive almost exclusively from colorectal, stomach or uterine cancers, even though most samples from these three cancer types clustered elsewhere on the PC plot. One feature particular to tumours from these three tissues is that they frequently display inactivation of the MMR pathway through mutation of MMR genes or hypermethylation of the MLH1 gene promoter [13] [14] [15] . Inactivation of MMR results in a high incidence of small insertions and deletions (indels) at simple sequence repeats-referred to as microsatellite instability (MSI) and used to identify MMR deficiency phenotypicallybut also in an increased SNV load (Extended Data Fig. 1c ).
The outlier colon, gastric and uterine cancer samples on the PC plot ( Fig. 1e and Extended Data Fig. 1d ) were almost always MSI samples (phenotypically scored as MSI-high (MSI-H)), suggesting MMR deficiency as the cause of their unusual regional mutation rate variation.
To understand how the regional mutation rate differs in these samples, we plotted their mutation densities along the genome. The regional rate variation was substantially decreased in these tumours compared to in other microsatellite-stable (MSS) tumours from the same tissues ( Fig. 2a-c) . The change towards more homogeneous mutation rates in MSI cancers was significant across many chromosomal regions, with ,72% of the genome being affected (1,977/2,748 1 Mb windows, Mann-Whitney test on pooled tissues, 10% FDR; examples in Fig. 2d and Extended Data Fig. 1e , f). Consistently, the regional rates in MSI cancers from all three tissues correlated poorly with replication timing ( Fig. 2e -g), gene expression levels and heterochromatin (Extended Data Fig. 2a-f ). Moreover, the slopes of the regression lines between binned replication timing and SNV rates revealed consistent changes in MSI cancer samples when calculated separately for intergenic and for genic (intronic) DNA in the whole genome sequences ( Fig. 2h , i). Very similar trends were observed in a broader set of 950 exome sequences of colorectal, uterine and gastric cancers (Extended Data Fig. 2g -j).
High mutation rates in uterine and colorectal cancers can also be caused by inactivation of the proofreading domain of DNA polymerase e 13,14 (PolE). Proofreading is a result of a 39-59 exonuclease activity that enhances the accuracy of PolE by excising incorrectly placed nucleotides during synthesis. MSS PolE tumours exhibited a significantly larger spread of the regional SNV density distribution than MSI tumours ( Fig. 2a, b ), even though their mutational load is typically higher (Extended Data Fig. 1c ). Similar conclusions are reached with stomach cancer 15 hypermutators of unknown aetiology ( Fig. 2c) . Thus, increased mutation supply does not explain the loss of regional mutation rate variability in MSI cancers.
The relative frequencies of 59 and 39 contexts of different SNVs-the mutation spectrum-are informative of the mutational processes operative in a particular cancer type 16 . We observed the previously reported 17 signatures of MMR deficiency in MSI cancers: C . T transitions in an NpCpG sequence context and C . A transversions at CpCpC (all mutations considered strand symmetrically). In addition, we report a general increase in the relative frequency of transitions in MSI genomes, wherein A . G increases preferentially when preceded or followed by a C, and C . T clearly increases most in the GpCpN context (Extended Data Fig. 3a ).
We examined how the different mutation spectra are distributed across the genome in MSI samples. The signatures most characteristic of MMR deficiency had a considerably flatter distribution in MSI tumours than in MSS or PolE-mutated tumours, whereas this was less the case for signatures not associated with MMR deficiency (Fig. 3a, b and Extended Data Fig. 3b, c) . Indeed, the more abundant a mutational context becomes specifically in MSI tumours, the more uniformly it is distributed with respect to replication timing in MSI samples ( Fig. 3c , R 2 5 0.45, P , 10 26 ) but not in MSS samples (Extended Data Fig. 3d , R 2 5 0.01).
Notably, however, many signatures not associated with MMR deficiency do flatten to some extent in MSI tumours. This suggests that the residual correlation with replication timing in MSI cancers ( Fig. 2e -g) might derive purely from the mutations originating before MMR inactivation. To test this idea, we used the proportion of mutations in MSIassociated contexts to sort the MSI samples by the proportion of their history spent in an MMR-deficient state (Methods). The proportion of mutations in MSI-associated contexts significantly correlates with how Figure 1 | Changes in megabase-scale regional mutation rate variation between tumour samples. a-e, PCA of the 1 Mb regional rates of 652 whole-genome sequences. a, Amount of variance conveyed by the prominent PCs. Baseline estimated by 'broken stick' method (Methods In the case of STAD, comparison is to PolE wild-type hypermutators (hyper). Data points in distributions are medians of relative mutation frequencies of each 1 Mb window across all cancer samples in group. **P # 0.01 by F-test for decrease in variance. Number of tumour samples given in brackets. s, standard deviation. d, Relative SNV frequencies across 1Mb windows of chromosome 1p in colorectal cancer (CRAD). Unbroken and dotted lines are the median across tumour samples and its 95% confidence interval, respectively. For each tumour sample, relative mutation frequencies are obtained by dividing by the mean of all 1 Mb windows. *FDR # 10% for rates significantly closer to unity in MSI-H samples (Mann-Whitney test). Striped bars are lowalignability regions (Methods). e-g, Reduced correlation of regional mutation rates to replication timing in MSI cancer samples. Genomic 1 Mb windows were pooled into five equal-frequency bins by the median Repli-Seq signal over 11 cell lines. For each bin, median and interquartile range of relative mutation rates across 1 Mb windows is shown. R 2 values are on original (not binned) data. *P , 0.01 for a difference of R, after Fisher Z-transform. Prior to binning, cancer samples in a group were combined by taking the median of the relative mutation frequencies in each 1 Mb window (as shown in d). h, i, Same as e-g but examined separately for genic (intronic) and intergenic regions. a is the slope of the regression line fit to binned data.
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flat the overall regional rates are with respect to replication timing in each sample ( Fig. 3d , R 2 5 0.37, P 5 0.0017). Importantly, this is also true for mutations in contexts that increase little or decrease in relative frequency in MSI genomes: all transversions (excluding C . A in CCN) and the transitions A . G in AAN and C . T in TCN ( Fig. 3e and Extended Data Fig. 3e , f; R 2 5 0.38-0.45, P , 0.0015). Thus, the greater the proportion of its history a tumour has spent in an MMR-deficient state, the flatter its distribution of mutations across the genome, and this flattening is observed for mutations in both MSI-associated and non-MSI-associated contexts.
To quantify more precisely the contribution of MMR to the observed regional mutation variation across the genome, we next estimated the time spent in the MMR-proficient and MMR-deficient states in each individual tumour. We used a simple model that assumes that genomewide mutation rates for each mutational context are equal across samples but allows for a distinct rate for each context in the MMR-proficient and MMR-deficient states (schematic in Fig. 4a, b ). We employed a genetic algorithm-based optimization that minimizes the difference to observed mutational signatures (Methods). After fitting a global set of rate parameters, this simple model captures 68% of the variance in differential mutational context usage across the MSI and a set of MSS cancer samples from all three MSI-prone cancer types (Extended Data Fig. 4 ). Importantly, the deconvolution recapitulated the known consequences of MMR deficiency on the mutational spectrum and the MSI status of each sample ( Fig. 4c, d) .
The model shows that the earlier MMR fails in the history of a tumour, the flatter its regional rate landscape is with respect to replication timing ( Fig. 4e , R 2 5 0.54, P , 10 24 ; examples in Fig. 4f ). Indeed, the inferred time of MMR failure predicts the loss of regional rate variability better than a simple proportion of mutations in MSI-prone contexts (R 2 5 0.37, Fig. 3d ). In addition, the 99% confidence interval of a linear fit to the points in Fig. 4e crosses the horizontal zero line-corresponding to a fully flat regional landscape-before the point at which all mutations are predicted to have arrived in the MMR-deficient state. This indicates that the mutations that arose after the inactivation of MMR in these tumours are not distributed with the characteristic regional variation across the genome. In the absence of MMR, mutation rates are not reduced in early replicating euchromatic regions compared to in late replicating heterochromatin.
Through an analysis of human tumours we have shown that MMR is more effective in euchromatic early replicating regions of the genome, suppressing the accumulation of mutations in these regions. MMR is known to be coupled to DNA replication, with elevated repair efficiency during S phase 18, 19 . Differences in DNA accessibility to the repair machinery [20] [21] [22] , the coupling of this machinery to the replication fork, or the time available for repair might contribute to the increased efficiency of repair in early replicating euchromatin. Across cell types, most active genes performing essential functions are euchromatic and replicated early [23] [24] [25] . It is thus sensible to envisage that enhanced MMR in euchromatin is a beneficial trait and one that has been selected for during evolution. 
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Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
TCGA genomes and calling somatic mutations. We downloaded aligned short reads (to hg19/GRCh37) for the available whole-genome sequences of tumours (n 5 630) and the matched normal tissue from the The Cancer Genome Atlas (TCGA) repository at CGHub. We then called somatic SNVs in each tumour-normal pair using Illumina's Strelka 1.0.6 workflow 26 . Strelka is a highly accurate caller, with a low false positive rate of SNVs at the default settings 27, 28 . We further increased the stringency of Strelka's post-call filtering to prevent spurious mutation calls. By default, Strelka requires that the overall confidence score (QSS_NT) is $15, that the fraction of filtered basecalls at the site (BCNoise) is ,40%, and also that the fraction of reads crossing site with spanning deletions (SpanDel) is ,75%. Here, we allow very few filtered or gapped reads at the site: BCNoise and SpanDel must both be ,3% for the tumour sample and ,10% for the normal tissue. Exceptionally, for extremely high-confidence calls (QSS_NT $45), BCNoise for the tumour sample may be ,6%. For TCGA leukaemia (LAML), we downloaded the called somatic SNVs from the corresponding publication 29 (n 5 50 samples).
Other whole-genome sequences. We downloaded the previously called somatic SNVs for whole-genome sequences (n 5 507) from the online supplementary material of Alexandrov et al. 16 ; these samples did not overlap the TCGA data set. Next, we downloaded the somatic SNVs from the whole-genome sequences in the International Cancer Genome Consortium (ICGC) v.15.1 database, in case the same genome sets were not already available in Alexandrov et al. 16 or TCGA; this encompasses the ICGC projects RECA-EU, MALY-DE and EOPC-DE (n 5 150 genomes). Finally, we removed all samples of B-cell lymphoma from the Alexandrov et al. 16 set due to a suspected partial overlap with a broader set in ICGC MALY-DE.
Filtering and dividing the genome into 1 Mb windows. To rule out errors due to misalignment of short reads, we masked out all regions in the genome defined in the 'CRG Alignability 36' track 30 , requiring a 36-nucleotide fragment to be unique in the genome even after allowing for two differing nucleotides. Next, we masked out the regions in the UCSC Browser blacklists (Duke and DAC), chosen for often exhibiting anomalous signals in next-generation sequencing experiments (http:// genome.ucsc.edu/cgi-bin/hgTrackUi?g5wgEncodeMapability). Finally, we discarded the exons (plus the flanking 2 nucleotides) of the UCSC gene set to avoid the signal stemming from selection on gene coding regions. Then we divided the genome into non-overlapping 1 Mb windows and discarded those with ,250 kb of DNA passing the above filters; we also exclude the remaining windows on chromosome Y (n 5 7) as Repli-Seq data were not available for them (see later). This yielded 2,748 1 Mb windows with an average of 664 kb highly alignable, non-blacklisted, non-exonic DNA per window. When determining SNV densities, the SNV counts in each window were divided by the effective length of the window (after masking) to obtain frequencies per Mb. The choice of 1 Mb resolution is a trade-off between the inclusion of low mutation burden tumour samples/types (better with coarser resolution) and the level of detail in describing the regional variability (better with finer resolution). Furthermore, replication timing is known to be organized in megabase-scale domains 23, 25 .
Conditions for inclusion in the final genome set. We merged the three sets of genomes (TCGA, Alexandrov et al. 16 and ICGC) and discarded the genomes that had fewer than 3,000 SNVs in the alignable regions of the genome in order to obtain more reliable regional mutation density estimates. This filter will completely remove the cancer types with very low SNV loads, such as TCGA thyroid, prostate, leukaemia, or kidney chromophobe. We also removed four cancer types represented by only a single genome with $3,000 SNVs (lower grade glioma (LGG) in TCGA, acute lymphoblastic leukaemia (ALL) and medulloblastoma in Alexandrov et al. 16 , and prostate cancer (EOPC-DE) in ICGC). Three TCGA uterine cancer UCEC genomes (TCGA-AP-A0LO, B5-A1MY, EY-A1GS) exhibited a high number of C . A changes at low clonal frequencies, consistent with known artefacts arising owing to 8-oxoG in oxidized DNA samples 31 [13] [14] [15] . Given previous reports stating that MSI-L samples are much more similar to MSS than to MSI-H in clinical and genomic features 32, 33 , we grouped MSI-L with MSS in all analyses. For 10 (of 64) colorectal cancers with the whole-genome sequence available, the MSI annotations were not supplied in the TCGA and we thus inferred them from the overall load of somatic SNVs and introns called by Strelka (see earlier). In particular, AD-A5EJ and QG-A5Z2 were putatively labelled as MSI tumours (both having .15,000 small indels and .40,000 SNVs) and QG-A5YW, QG-A5YX, A6-A56B, QG-A5YV, A6-A566, QG-A5Z1, A6-A567 and A6-A565 were putative MSS tumours (all with ,1,500 small indels and ,15,000 SNVs). In case of uterine and stomach cancers, all samples with whole-genome sequences were assigned an MSI/MSS label by the TCGA. MSI and MSS PolE mutants. The PolE status of samples was inferred by requiring a non-synonymous somatic mutation called in the POLE gene. Consistent with previous reports 32 , the MSI tumours with a PolE mutation have an overall mutational load similar to MSI PolE wild-type samples, unlike the PolE-mutated MSS samples, which are ultramutated 13, 14 . We thus grouped the MSI PolE mutants with MSI PolE wild-type samples, except in the case of two (out of three) MSI PolE mutants in uterine cancer (UCEC: AX-A0J1 and AP-A051). These samples had a much higher mutational load than other MSI UCEC samples (leftmost UCEC columns in Extended Data Fig. 1c) . Moreover, they also had a mutational signature not consistent with other MSIs-in particular, the relative abundance of A . G transitions was low in these samples (11% and 13%), much less than in ten other UCEC MSIs (average 34%, range 23-60%). We thus omitted these two MSI1PolE UCEC samples from all analyses that involved examining mutational signatures (corresponding to Figs 3 and 4 , and Extended Data Figs 3 and 4) , thus forming the set of 24 MSI samples used therein, of which 10 were CRAD, 10 were UCEC and 4 were STAD. Cancer exome sequences. The called somatic mutations from exome sequencing (MAF files) were downloaded from the TCGA for the COAD/READ (CRAD), UCEC and STAD cancer types in October 2014. For each tumour sample (TCGA patient), we selected the newest available MAF that had mutation data for that sample, and we did not load further mutation data for that sample from other MAFs (files listed in Supplementary Table 1 ). Next, we assigned MSI-H, MSI-L or MSS status to the exomes from the same data sources used for the whole genomes (see earlier) and discarded samples for which the MSI status was not known. This left 950 samples, of which 195 were MSI-H, and the rest were MSS or MSI-L (pooled together). PolE status was not inferred for exomes. The genomic mask for the exome analysis was constructed differently than for whole genomes: we similarly used the 'CRG Alignability 36' filter and the two UCSC blacklists. However, we excluded all DNA except the protein coding exons (but not exons of commonly mutated cancer genes, which were also excluded). Finally, we retained only the 1 Mb windows with at least 5 kb of alignable, non-backlisted exonic DNA. This reduced the initial set of 2,748 windows (for the whole-genome analysis) to 1,709 windows for the exome analysis. Density of mutations was expressed per Mb of available DNA in each window, and again normalized by dividing by the average of all windows in a sample. For the analysis where we considered each exome separately (Extended Data Fig. 2j ), we limited the analysis to exomes with $50 SNVs in the selected genomic windows. Gene expression data. The expression levels in tumours were downloaded from the TCGA RnaSeqV2 data sets 34 , where they are expressed as transcript per million (TPM) 35 values for each gene. For 15 TCGA cancer types that had RnaSeqV2 data available, we downloaded TPM levels for those tumour samples for which we had called whole-genome somatic SNVs, in total 8-92 RnaSeqV2 samples per cancer type (average 5 29). The TPM levels of genes overlapping (including partially) each 1 Mb window were averaged for a tumour sample, and we then averaged over all samples of each cancer type to get the final expression level for that 1 Mb window in that cancer type; if lower than 0.01 TPM, it was adjusted to 0.01 TPM. The overall, cross-tissue 1 Mb expression levels (in Extended Data Fig. 2a-c) are then the medians across 15 cancer types.
The tissue specificity (TS) of gene expression of 1 Mb windows for a particular cancer type (in Fig. 1g ) is the log 2 ratio of TPM in that cancer type and the average TPM across all cancer types. In comparing the TS of gene expression to the TS of mutation rates, we limited the analyses to the 2,442/2,748 1 Mb windows that were at least somewhat expressed (.0.01 TPM) in at least one examined cancer type. Moreover, we excluded chromosome Y for consistent treatment with the replication timing TS analysis (see later). Finally, we considered only the eight cancer types (seven tissues) with significant shifts in the PC3 of regional mutation rates. Replication timing data. We downloaded the Repli-Seq measurements 36 (as waveletsmoothed signal 37 ) of ENCODE cell lines from the UCSC Genome Browser (also available in the Gene Expression Omnibus under accession number GSE34399). To avoid biasing the sample, we excluded multiple lymphoblastoid cell lines and retained Gm12878 as a representative. We computed the average Repli-Seq signal within 1 Mb genome windows of the remaining 11 cell lines, except chromosome Y, which was unavailable in the original data. The resulting values ranged from 0-100, where higher values indicate earlier replication. The overall, cross-tissue replication timing signal (used for genome binning in Figs 2 and 3 and Extended Data Figs 2 and 3) is the median value across the 11 cell lines.
The TS of replication timing in a cell line (in Fig. 1f) is the difference between the Repli-Seq signal of that cell line and the average signal across all cell lines. For the TS analysis, we considered those cell lines that (1) could be matched to a cancer type, based on their tissue of origin, and that (2) corresponded to one of the eight cancer types found to have a significant shift in PC3 of the regional mutation rates (Fig. 1e) . In particular, replication timing TS in MCF7 cells served as a proxy for BRCA LETTER RESEARCH (breast cancer), BJ cells for SKCM (melanoma), IMR-90 cells for LUSC/LUAD (lung cancers), HEP G2 cells for LIHC (liver cancer) and Gm12878 cells for DLBC (lymphoma). For consistency with the gene expression TS analyses, we considered the same set of 1 Mb windows (see earlier) in the replication timing TS analysis. Heterochromatin data. We downloaded the RoadMap epigenomics H3K9me3 ChIP-seq signal for a diverse set of healthy tissues or cell lines from the Gene Expression Omnibus, encompassing: GSM621651 (adult kidney), GSM537710 (adult liver), GSM670028 (mesenchymal stem cells), GSM772917 (CD4 naive), GSM669939 (fetal lung), GSM450266 (H1 cell line), GSM521914 (IMR-90 cell line). In addition, we include the H3K9me3 levels from Barski et al. 38 that were previously shown to have a strong correlation to regional mutation rates in cancer 2 . We calculated the mean H3K9me3 signal in 1 Mb windows for each sample and trimmed the distribution at the 99.9th percentile. Then we log-transformed the values and found the median over eight tissues/cell lines to get the overall H3K9me3 levels used for binning (in Extended Data Fig. 2d-f ). Slopes over genomic bins. We used the overall, cross-tissue Repli-Seq signal to create five equal-frequency (same number of 1 Mb windows) genome bins for further analyses. Additional sets of bins were created also for the gene expression and for the heterochromatin signal (Extended Data Fig. 2a-f ). The slope of a regression line fitted through the average 1 Mb relative mutation rates of each bin is a measure of the association of mutation rates to replication timing (Figs 2-4) . This measure has the desirable property of being robust to differences in the overall mutation load between smaller groups of tumour samples or individual genomes, or between mutational signatures.
For the analysis in which intergenic and genic regions were examined separately in MSI and MSS cancers, we used the UCSC gene set to define these regions. Since the gene exons had already been excluded in a genome pre-processing step, the genic regions effectively consist only of introns. Only for the purposes of this intergenic versus genic analysis, we relaxed the requirement of $250 kb (of total alignable DNA) per 1 Mb window to $100 kb (either intronic or intergenic) alignable DNA per 1 Mb. When calculating relative mutation rates, regardless whether we were analysing intergenic or intronic mutations, each sample was always normalized by dividing by the mean of the aggregate (intergenic plus intronic DNA) SNVs rates across all its windows. The five Repli-Seq bins were the same as in the wholegenome analysis. Statistical analysis. PCA was performed in R 3.1.1 (R Core Team) and in XLStat 2014.2 (Addinsoft) on the relative 1 Mb mutation rates of each tumour sample, where tumour samples were features (columns in data table), and 1 Mb windows were examples (rows). To find the relative rates, first the SNV densities per Mb of alignable, non-exonic, non-blacklisted DNA (see earlier) were determined for each 1 Mb window in every tumour sample. Then, these densities in each sample were normalized by dividing by the mean SNV density of all windows in that sample. Thus, the relative mutation frequencies .1 correspond to above-average SNV densities in a tumour sample, and ,1 to below-average densities. The approximate 95% confidence intervals of the median (across tumour samples: Fig. 2d and Extended Data Fig. 1e , f) for the 1 Mb windows were estimated using the formula 61.58*IQR/ sqrt(n_samp), as defined in the R function boxplot.stats and references therein. In the PCA, given that the tumour samples were features (columns) and the 1 Mb windows were examples (rows), the PCs will be linear combinations of tumour samples, and the loadings of the samples on PCs 3 and 4 are shown in Fig. 1e . The expected (baseline) per cent variance in each PC stemming from noise in data was estimated using the 'broken stick' method, found to outperform related approaches 39 . The cancer types were tested for shifts in PC3 loadings using a Mann-Whitney test (two-tailed), where the loadings of samples in one cancer type were contrasted to the loadings of samples in all other types. Mutational signatures. As in previous work 16 Fig. 3a shows their relative usage, as percentage of SNVs observed in each context. The MSI propensities of contexts (in Fig. 3 and Extended Data Fig. 3) were defined as the log 2 ratio of the absolute mutation frequency (per Mb) of a context in the MSI samples to its mutation frequency in the MSS samples.
DNA word frequencies do not necessarily occur equally frequently in genomes; for instance, the CpG dinucleotide is rare. Moreover, they may vary in frequency across the genome, as is most evident in the global G1C content variation. The outcome of analyses that compare how mutational context usage co-varies with replication timing (Figs 3 and 4 and Extended Data Figs 3 and 4 ) may be affected by this. Therefore, we normalized the mutation frequencies in different contexts by dividing each by the number of corresponding nucleotides at risk in each 1 Mb window (only nucleotides passing the alignability mask described earlier). On data normalized thusly, we determined the strength of association to replication timing via the slope of the line fitted to Repli-Seq bins, as described earlier. (Of note, as with the full set of mutations, here also all 1 Mb window values were divided by the genome average before binning.) In case different contexts needed to be combined, the Repli-Seq slopes were determined for each context separately and then the slopes were averaged for the combined context. Determining time of MMR failure in samples. We aimed to determine the relative time spent in the MMR-proficient and MMR-deficient states for each of the 24 MSI samples: 10 CRAD, 4 STAD and 10 UCEC (see earlier) by deconvoluting their mutational signatures into MSI and MSS components. To these 24 MSI samples, we added a further 24 MSS samples, matched by cancer type, while excluding the PolE ultramutators (in CRAD/UCEC) or otherwise hypermutated (in STAD) samples.
To reduce the number of parameters that needed to be estimated, we pooled the contexts with different 39 nucleotides together (this corresponds to how bars are drawn in Extended Data Fig. 3a ). An exception were the NCG . NTG changes (deamination of CpG dinucleotides) that were kept separate from other NCN . NTN changes, which are here denoted as NCH (H 5 A, C or T). This yields a total of 28 contexts, for each of which we estimated a pre-MMR failure relative mutation rate (a) and a post-MMR failure relative mutation rate (b). The rates were assumed to be constant across samples and in time. Each sample may, however, spend a different fraction of time in the pre-MMR-failure state (z). Thus the total number of parameters to estimate is 28 (a for contexts) 1 28 (b for contexts) 1 24 (z for MSI samples) 1 24 (z for MSS samples) 5 104.
For a set of 104 parameters, the expected relative frequency of a context (ctx) in a sample (samp) may be calculated as (a ctx 3 z samp ) 1 b ctx 3 (1 2 z samp ). A measure of goodness of fit for a candidate set of parameters was the negative root mean squared difference between these expected relative frequencies and the observed relative frequencies of use of 28 different contexts across the 48 samples. We used a genetic algorithm-based optimization to maximize the fit to the observed mutational spectra, as implemented in the rgenoud 5.7-12 package 40 in R. The parameters were at defaults, except max.generations 5 500, gradient.check 5 FALSE, wait.generations 5 100 and BFGS 5 FALSE. The starting populations of solutions were generated with rnorm(1, 0.2, 0.2) for the rates a, rnorm(1, 0.5, 0.3) for the rates b and rnorm(1, 0.5, 0.3) for the times z.
The optimization was run 100 times with different random seeds for function genoud. The algorithm always converged to one of two clusters of very similar solutions with very similar goodness-of-fit scores and that predicted nearly identical mutational spectra for the 48 tumour samples (Extended Data Fig. 4b-d ). Upon examining the coefficients of the solutions and schematic diagrams of the accumulation of mutations in time (Extended Data Fig. 4e-j) , it becomes evident that the two sets of solutions are equivalent, with symmetrical a and b mutation rates, and also the pre-MMR failure time (z) and the post-MMR failure time (1 2 z) across all samples. As the representative solution used in further analysis, we take the median a, b and z coefficients across solutions of the cluster in which the MSI-specific mutational signature GCH . GTH is predicted to increase in rate after MMR failure. In no other way was the algorithm aware of which signatures are specific to MSI tumours, or which of the 48 samples were MSI and which were MSS. The algorithm could, in principle, be used to deconvolute other mutational processes that have a distinct time of (de)activation during carcinogenesis. Its practical use would, however, probably be limited to those processes that, like MSI, have a very distinct mutational signature. 
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Extended Data Figure 4 | The deconvolution of MSI mutational spectra robustly converges onto two equivalent solutions. a, Agreement of the observed relative frequencies of mutational contexts in each tumour sample with the predictions of model 1 (having median a, b and z coefficients across all solutions in cluster 1). b, Sets of best-fit solutions determined in a hundred optimization runs initialized with different starting conditions. The solutions cluster into two homogeneous clusters (Pearson R . 0.9 between .90% of the solutions within a cluster, in UPGMA hierarchical clustering). c, d, Solutions within both clusters have similar fit to observed data (c) and make extremely similar predictions for mutation spectra in tumour samples (d). e-h, Similar to Fig. 4a, b . Example mutation accumulation diagrams for two mutation contexts typical of MSI tumours, shown for an example MSI tumour TCGA-BR-4280 (e, g) and for an MSS tumour TCGA-CD-8529 (f, h). i, j, Values of the parameters in two solution clusters, with medians and interquartile ranges (shown as whiskers). Each solution encompasses 104 parameters: relative mutation rates a and b for each of 28 mutational contexts (i), and the relative pre-MMR failure time z for each tumour sample of the 24 MSI and 24 MSS samples (j).
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